Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Fycompa® Approved in China for Primary Generalized Tonic-clonic Seizures
Details : Fycompa is a selective, non-competitive AMPA glutamate receptor antagonist indicated for treating partial-onset seizures and primary generalized tonic-clonic seizures in patients aged 12 & older.
Brand Name : Fycompa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 13, 2024
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launches in Japan
Details : Fycompa (perampanel) is a selective, non-competitive AMPA glutamate receptor antagonist indicated for treating partial-onset and primary generalized tonic-clonic seizures in patients aged 12 & older.
Brand Name : Fycompa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 18, 2024
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Antiepileptic Drug Fycompa® Injection Formulation Approved in Japan
Details : Fycompa (perampanel) is a selective, non-competitive AMPA glutamate receptor antagonist indicated for treating partial-onset and primary generalized tonic-clonic seizures in patients aged 12 & older.
Brand Name : Fycompa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 18, 2024
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akums gets DCGI Approval for Perampanel Oral Suspension
Details : Perampanel oral suspension is first-in-class anti-epileptic agent, With epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated w...
Brand Name : Fycompa-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 27, 2023
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
Details : The completion of the acquisition, strengthens the company's Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy. Fycompa (perampanel), an oral medication, is a selective non-competitive AMPA receptor antag...
Brand Name : Fycompa
Molecule Type : Small molecule
Upfront Cash : $160.0 million
January 25, 2023
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Divestment
Details : Fycompa (perampanel) is a non-competitive AMPA glutamate receptor antagonist used to treat partial-onset seizures with or without secondarily generalized seizures, and as adjunctive treatment of primary generalized tonic-clonic seizures in patients with ...
Brand Name : Fycompa
Molecule Type : Small molecule
Upfront Cash : $160.0 million
December 20, 2022
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Fycompa (perampanel), an oral medication, is a selective non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist.
Brand Name : Fycompa
Molecule Type : Small molecule
Upfront Cash : $160.0 million
December 19, 2022
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Perampanel (Fycompa) is first-in-class AED with epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist reduces neuronal hyperexcitation.
Brand Name : Fycompa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2022
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Perampanel is first-in-class anti-epileptic agent, With epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures.
Brand Name : Fycompa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2022
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Tsukuba Research Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Fycompa is a first-in-class AED discovered at Eisai’s Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures.
Brand Name : Fycompa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 31, 2022
Lead Product(s) : Perampanel
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Tsukuba Research Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?